EARLY-STAGE MESOTHELIOMA
Clinical trials for EARLY-STAGE MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new EARLY-STAGE MESOTHELIOMA trials appear
Sign up with your email to follow new studies for EARLY-STAGE MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Withdrawn trial aimed to halt rare cancer in High-Risk families
Disease control TerminatedThis study aimed to test if an oral drug called APG-115 could stop or slow the growth of early-stage mesothelioma in people with a specific inherited gene mutation (BAP1). Participants would have taken the drug at home in repeating cycles while undergoing regular scans and biopsi…
Matched conditions: EARLY-STAGE MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Pill aims to halt early cancer in High-Risk patients
Disease control TerminatedThis study is testing whether an oral drug called INQOVI can stop or improve very early-stage mesothelioma in people born with a specific gene mutation (BAP1) that makes them highly likely to develop this cancer. Participants take the pill for six months while doctors closely mon…
Matched conditions: EARLY-STAGE MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC